<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00990600</url>
  </required_header>
  <id_info>
    <org_study_id>ADONE</org_study_id>
    <secondary_id>EUDRACT NUMBER: 2007-007839-33</secondary_id>
    <nct_id>NCT00990600</nct_id>
  </id_info>
  <brief_title>QoL and Adherence to One-pill Once-a-day HAART</brief_title>
  <acronym>ADONE</acronym>
  <official_title>Adherence to a One Pill, Once-a-day Antiretroviral Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A.O. Ospedale Papa Giovanni XXIII</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>A.O. Ospedale Papa Giovanni XXIII</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective of the study is:

      To verify if simplification of the antiretroviral regimen, measured as the reduction of pill
      burden alone, may affect adherence rate of patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of adherence to HAART</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>QoL (VAS scale) preferences of patients virologic and immunologic outcomes</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>HIV Infection</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Simplified one pill regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination of tenofovir + emtricitabine + efavirenz</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>reduced number of pills</intervention_name>
    <description>Switch to a fixed dose combination one pill/daily HAART</description>
    <arm_group_label>Simplified one pill regimen</arm_group_label>
    <other_name>efavirenz EFV</other_name>
    <other_name>emtricitabine FTC</other_name>
    <other_name>tenofovir TDF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Informed consent signed

          -  Effective ongoing treatment (HIV-RNA &lt; 50 copies/ml) for at least three months

          -  Being on a stable HAART regimen based either on two possible drug associations:

               -  3TC/FTC + TDF + EFV

               -  FTC/TDF (fixed dose combination) + EFV

          -  No previous documented virologic failure

        Exclusion Criteria:

          -  Childbearing or breastfeeding. Women of childbearing potential will be asked to adopt
             effective contraceptive methods or behaviours

          -  Any ongoing grade 4 laboratory abnormality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franco Maggiolo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedali Riuniti, Bergamo</affiliation>
  </overall_official>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2009</study_first_submitted>
  <study_first_submitted_qc>October 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2009</study_first_posted>
  <last_update_submitted>October 28, 2009</last_update_submitted>
  <last_update_submitted_qc>October 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Franco Maggiolo MD</name_title>
    <organization>Divisione di Malattie Infettive, Ospedali Riuniti, Bergamo</organization>
  </responsible_party>
  <keyword>adherence</keyword>
  <keyword>Qol</keyword>
  <keyword>virologic efficacy</keyword>
  <keyword>immunologic efficacy</keyword>
  <keyword>patients' preference</keyword>
  <keyword>once-daily</keyword>
  <keyword>HAART</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

